SEC Comment Letter for Korro Bio, (KRRO) — Mar 18, 2026
Korro Bio, Inc.
Date: March 18, 2026 · CIK: 0001703647 · Accession: 0000000000-26-002740
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294298
Letter
Re: Korro Bio, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294298 Dear Ram Aiyar:
March 18, 2026
Ram Aiyar President, Chief Executive Officer and interim Chief Financial Officer Korro Bio, Inc. 60 First Street, 2nd Floor, Suite 250 Cambridge, MA 02141
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Marianne Sarrazin, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 18, 2026 Ram Aiyar President, Chief Executive Officer and interim Chief Financial Officer Korro Bio, Inc. 60 First Street, 2nd Floor, Suite 250 Cambridge, MA 02141 Re: Korro Bio, Inc. Registration Statement on Form S-3 Filed March 13, 2026 File No. 333-294298 Dear Ram Aiyar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marianne Sarrazin, Esq. </TEXT> </DOCUMENT>